More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

What does it take to implement an end-to-end-business model, meaning a single CDMO/CMO providing development and manufacturing services for both active pharmaceutical ingredients (APIs) and drug products? DCAT Value Chain Insights gains input from...

The US Food and Drug Administration (FDA) has approved 14 new molecular entities (NMEs) thus far in 2019, behind the pace of last year’s record-setting 59 NME approvals. Which drugs have made the mark thus far and are there potential blockbusters...

What have been the key deals among pharmaceutical companies thus far in 2019? From pending mega mergers of Bristol-Myers Squibb and Celgene and AbbVie and Allergan to Gilead’s large-scale R&D pact with Galapagos, DCAT Value Chain Insights...

Whether on the “buy” or “sell” side, using the right negotiation tools and strategies is crucial. In DCAT Sharp Sourcing LIVE, a webinar from DCAT livestreamed from London, Niro Sivanathan, PhD, Associate Professor, London Business School, shares...

The pharma industry is providing feedback on the FDA’s draft guidance on continuous manufacturing, with GSK, Eli Lilly, AstraZeneca, J&J, the Association for Accessible Medicines, CEFIC’s Active Pharmaceutical Ingredients Committee, and...

Albert Bourla, who became CEO of Pfizer in January, has made his first large-scale deal as CEO: a pending $11.4-billion acquisition of Array BioPharma, which specializes in small-molecule cancer drugs. How does the move fit into the company’s...

Sanofi CEO Olivier Brandicourt has announced plans to retire, effective September 1, with Paul Hudson, head of Novartis' pharmaceutical division, taking the helm. With Sanofi facing competition in its diabetes-drug franchise and recent moves in...

The emergence of mega-contract development and manufacturing organizations (CDMOs), limited acquisition targets of CDMOs due to tight capacity, and burgeoning trade issues are key issues influencing deal-making in the CDMO market. Mergers and...

High-potency manufacturing and capabilities for early-stage development are among recent investment trends by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs) of intermediates and small-molecule...